Global InformationParsatuzumab information
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | EGFL7 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII |
|
| Chemical and physical data | |
| Formula | C6560H10130N1758O2046S46 |
| Molar mass | 147836.22 g·mol−1 |
Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.[1]
This drug was developed by Genentech/Roche.[2]
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Parsatuzumab, American Medical Association.